Cargando…
Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology
Herpes zoster, also known as shingles, is a distinctive clinical condition caused by the reactivation of latent varicella zoster (chickenpox) virus following an initial infection. Approximately 1 million cases of herpes zoster occur annually in the US, and one in every three people develops herpes z...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036669/ https://www.ncbi.nlm.nih.gov/pubmed/27703368 http://dx.doi.org/10.2147/JMDH.S106340 |
_version_ | 1782455596073615360 |
---|---|
author | Mallick-Searle, Theresa Snodgrass, Brett Brant, Jeannine M |
author_facet | Mallick-Searle, Theresa Snodgrass, Brett Brant, Jeannine M |
author_sort | Mallick-Searle, Theresa |
collection | PubMed |
description | Herpes zoster, also known as shingles, is a distinctive clinical condition caused by the reactivation of latent varicella zoster (chickenpox) virus following an initial infection. Approximately 1 million cases of herpes zoster occur annually in the US, and one in every three people develops herpes zoster during their lifetime. Postherpetic neuralgia is a neuropathic pain syndrome characterized by pain that persists for months to years after resolution of the herpes zoster rash. It stems from damage to peripheral and central neurons that may be a byproduct of the immune/inflammatory response accompanying varicella zoster virus reactivation. Patients with postherpetic neuralgia report decreased quality of life and interference with activities of daily living. Approaches to management of postherpetic neuralgia include preventing herpes zoster through vaccination and/or antiviral treatment, and administering specific medications to treat pain. Current guidelines recommend treatment of postherpetic neuralgia in a hierarchical manner, with calcium channel α2-δ ligands (gabapentin and pregabalin), tricyclic antidepressants (amitriptyline, nortriptyline, or desipramine), or topical lidocaine patches as first-line drugs. The safety and tolerability of pharmacologic therapies for pain are important issues to consider as postherpetic neuralgia affects primarily an older population. Patients should be educated on appropriate dosing, titration if applicable, the importance of adherence to treatment for optimal effectiveness, and possible side effects. Health-care professionals play a key role in helping to ameliorate the pain caused by postherpetic neuralgia through early recognition and diligent assessment of the problem; recommending evidence-based treatments; and monitoring treatment adherence, adverse events, responses, and expectations. Nurse practitioners are especially crucial in establishing communication with patients and encouraging the initiation of appropriate pain-relieving treatments. |
format | Online Article Text |
id | pubmed-5036669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50366692016-10-04 Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology Mallick-Searle, Theresa Snodgrass, Brett Brant, Jeannine M J Multidiscip Healthc Review Herpes zoster, also known as shingles, is a distinctive clinical condition caused by the reactivation of latent varicella zoster (chickenpox) virus following an initial infection. Approximately 1 million cases of herpes zoster occur annually in the US, and one in every three people develops herpes zoster during their lifetime. Postherpetic neuralgia is a neuropathic pain syndrome characterized by pain that persists for months to years after resolution of the herpes zoster rash. It stems from damage to peripheral and central neurons that may be a byproduct of the immune/inflammatory response accompanying varicella zoster virus reactivation. Patients with postherpetic neuralgia report decreased quality of life and interference with activities of daily living. Approaches to management of postherpetic neuralgia include preventing herpes zoster through vaccination and/or antiviral treatment, and administering specific medications to treat pain. Current guidelines recommend treatment of postherpetic neuralgia in a hierarchical manner, with calcium channel α2-δ ligands (gabapentin and pregabalin), tricyclic antidepressants (amitriptyline, nortriptyline, or desipramine), or topical lidocaine patches as first-line drugs. The safety and tolerability of pharmacologic therapies for pain are important issues to consider as postherpetic neuralgia affects primarily an older population. Patients should be educated on appropriate dosing, titration if applicable, the importance of adherence to treatment for optimal effectiveness, and possible side effects. Health-care professionals play a key role in helping to ameliorate the pain caused by postherpetic neuralgia through early recognition and diligent assessment of the problem; recommending evidence-based treatments; and monitoring treatment adherence, adverse events, responses, and expectations. Nurse practitioners are especially crucial in establishing communication with patients and encouraging the initiation of appropriate pain-relieving treatments. Dove Medical Press 2016-09-21 /pmc/articles/PMC5036669/ /pubmed/27703368 http://dx.doi.org/10.2147/JMDH.S106340 Text en © 2016 Mallick-Searle et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Mallick-Searle, Theresa Snodgrass, Brett Brant, Jeannine M Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology |
title | Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology |
title_full | Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology |
title_fullStr | Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology |
title_full_unstemmed | Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology |
title_short | Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology |
title_sort | postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036669/ https://www.ncbi.nlm.nih.gov/pubmed/27703368 http://dx.doi.org/10.2147/JMDH.S106340 |
work_keys_str_mv | AT mallicksearletheresa postherpeticneuralgiaepidemiologypathophysiologyandpainmanagementpharmacology AT snodgrassbrett postherpeticneuralgiaepidemiologypathophysiologyandpainmanagementpharmacology AT brantjeanninem postherpeticneuralgiaepidemiologypathophysiologyandpainmanagementpharmacology |